AKT1 and neoplasm: In addition, our study finds that LXR-α is regulated by the EGFR/AKT/FOXO3A axis and a combination of EGFR inhibitor Afatinib and GW3965 simultaneously increases and activates LXR-α, resulting in an increase of tumor suppressors and, ultimately, tumor inhibition.